Treatment Research › Pharmaceutical Treatments

Naltrexone Reduces Brain's Response to Craving

Researchers at Harvard-affiliated McLean Hospital have produced the first evidence that the opioid blocker extended-release injectable naltrexone (XR-NTX) is able to reduce the brain's response to cues that may cause alcoholics to relapse. In data presented at the annual meeting of the American Psychiatric Association, Scott Lukas, PhD, director of the Neuroimaging Center at McLean, located in Belmont, Mass., said the findings help in the understanding of how XR-NTX works in reducing the craving for alcohol and may potentially help predict which people will respond best to the drug.

Continue reading

Fears Over Naltrexone Unfounded, Study Finds

Fears over a drug that can be used to treat alcohol addiction are unfounded, according to its first ever systematic review, led by academics at The University of Manchester. Though the study found no evidence of any serious side effects linked to Naltrexone, many doctors hold back from prescribing the drug, often citing liver toxicity as a reason

Continue reading


Page top